Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of MEI Pharma patents

Patents where

Current Assignee

Name

MEI Pharma

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11304953 Combination therapy	Patent 11304953 was granted and assigned to MEI Pharma on April, 2022 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	11304953	April 19, 2022
‌ US Patent 10064868 (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases	Patent 10064868 was granted and assigned to MEI Pharma on September, 2018 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	10064868	September 4, 2018
‌ US Patent 10335415 (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases	Patent 10335415 was granted and assigned to MEI Pharma on July, 2019 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	10335415	July 2, 2019
‌ US Patent 11351176 Combination therapy	Patent 11351176 was granted and assigned to MEI Pharma on June, 2022 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	11351176	June 7, 2022
‌ US Patent 11583514 Isoflavonoid compounds and methods for the treatment of cancer	Patent 11583514 was granted and assigned to MEI Pharma on February, 2023 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	11583514	February 21, 2023
‌ US Patent 9056852 (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases	Patent 9056852 was granted and assigned to MEI Pharma on June, 2015 by the United States Patent and Trademark Office.		MEI Pharma	United States Patent and Trademark Office	9056852	June 16, 2015
‌ US Patent 11400097 (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases	Patent 11400097 was granted and assigned to MEI Pharma on August, 2022 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	11400097	August 2, 2022
‌ US Patent 9402829 Benzimidazole derivatives: preparation and pharmaceutical applications	Patent 9402829 was granted and assigned to MEI Pharma on August, 2016 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	9402829	August 2, 2016
‌ US Patent 9717713 Benzimidazole derivatives: preparation and pharmaceutical applications	Patent 9717713 was granted and assigned to MEI Pharma on August, 2017 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	9717713	August 1, 2017
‌ US Patent 10201527 Benzimidazole derivatives: preparation and pharmaceutical applications	Patent 10201527 was granted and assigned to MEI Pharma on February, 2019 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	10201527	February 12, 2019
‌ US Patent 10973799 Isoflavonoid compositions and methods for the treatment of cancer	Patent 10973799 was granted and assigned to MEI Pharma on April, 2021 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	10973799	April 13, 2021
‌ US Patent 10603324 (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases	Patent 10603324 was granted and assigned to MEI Pharma on March, 2020 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	10603324	March 31, 2020
‌ US Patent 10369132 Isoflavonoid compositions and methods for the treatment of cancer	Patent 10369132 was granted and assigned to MEI Pharma on August, 2019 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	10369132	August 6, 2019
‌ US Patent 8957109 Chroman derivatives, medicaments and use in therapy	Patent 8957109 was granted and assigned to MEI Pharma on February, 2015 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	8957109	February 17, 2015
‌ US Patent 10105346 Isoflavonoid compounds and methods for the treatment of cancer	Patent 10105346 was granted and assigned to MEI Pharma on October, 2018 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	10105346	October 23, 2018
‌ US Patent 9024029 Benzimidazole derivatives: preparation and pharmaceutical applications	Patent 9024029 was granted and assigned to MEI Pharma on May, 2015 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	9024029	May 5, 2015
‌ US Patent 9198895 Chroman derivatives, medicaments and use in therapy	Patent 9198895 was granted and assigned to MEI Pharma on December, 2015 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	9198895	December 1, 2015
‌ US Patent 9266882 Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications	Patent 9266882 was granted and assigned to MEI Pharma on February, 2016 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	9266882	February 23, 2016
‌ US Patent 10626092 Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide and uses thereof		MEI Pharma	MEI Pharma	United States Patent and Trademark Office	10626092	April 21, 2020
‌ US Patent 9981936 Isoflavonoid compositions and methods for the treatment of cancer	Patent 9981936 was granted and assigned to MEI Pharma on May, 2018 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	9981936	May 29, 2018
‌ US Patent 8901149 Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications	Patent 8901149 was granted and assigned to MEI Pharma on December, 2014 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	8901149	December 2, 2014
‌ US Patent 9138478 Substituted chroman derivatives, medicaments and use in therapy	Patent 9138478 was granted and assigned to MEI Pharma on September, 2015 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	9138478	September 22, 2015
‌ US Patent 9708283 Isoflavonoid compositions and methods for the treatment of cancer	Patent 9708283 was granted and assigned to MEI Pharma on July, 2017 by the United States Patent and Trademark Office.		MEI Pharma	United States Patent and Trademark Office	9708283	July 18, 2017
‌ US Patent 9381186 Substituted chroman derivatives, medicaments and use in therapy	Patent 9381186 was granted and assigned to MEI Pharma on July, 2016 by the United States Patent and Trademark Office.	MEI Pharma	MEI Pharma	United States Patent and Trademark Office	9381186	July 5, 2016
‌ US Patent 9663484 Isoflavonoid compounds and methods for the treatment of cancer	Patent 9663484 was granted and assigned to MEI Pharma on May, 2017 by the United States Patent and Trademark Office.		MEI Pharma	United States Patent and Trademark Office	9663484	May 30, 2017

Results per page:

29 results

0 selected

29 results

0 selected